p53基因(今又生(R))联合支气管动脉化疗治疗肺癌15例近期疗效观察

目的探讨瘤内注射或经支气管动脉灌注p53基因联合支气管动脉灌注化疗(BAI)治疗肺癌的安全性、疗效和给药途径.方法经病理证实的15例肺癌,首先在CT引导下经皮穿刺瘤内注射或经支气管动脉灌注p53基因(今又生(R)),2～5天后,行BAI灌注化疗药物;然后根据病情变化再次进行基因治疗和/或BAI.治疗后常规使用螺旋CT定期复查,评价治疗效果.结果全部15例患者均完成上述治疗,并接受随访2～11个月.有效率(CR PR)46.7%(7/15),1例肺部肿块消失,6例肺部肿块缩小,3例纵隔淋巴结缩小,1例胸水减少,仅1例观察到肿瘤长大,14例临床症状有不同程度缓解93.3%(14/15).p53治疗后6例出现发热(38℃～40℃),未观察到基因药物的其它严重副作用,无严重操作有关并发症出现.结论本研究结果初步显示,作为肿瘤综合治疗的一部分,p53基因治疗与BAI联合应用,是一种治疗肺癌安全、有效的方法,提高了BAI的治疗效果.经皮瘤内注射p53是否为一种较好的给药途径值得进一步探讨.     

Clinical Evaluation of Automatic Tachycardia Diagnosis by an Implanted Device

Reliable discrimination between sinus tachycardia (ST) and pathologic tachycardia has been a major problem for automatic implantable antitachycardia devices. In patients whose sinus response to activity is as rapid or faster than their pathologic tachycardia (rate crossover), these unsophisticated devices deliver the programmed tachycardia response to either the pathologic or sinus tachycardia. Over a one-year period, 50 Intermedics Intertach Model 262–12 antitachycardia pulse generators were implanted to evaluate the specificity of a new group of tachycardia recognition algorithms. Patients were subjected to exercise testing and noninvasive programmed stimulation to demonstrate the efficacy of this new approach. The five recognition algorithms tested were various combinations of the following criteria: high rate HR), sudden onset (SO), rate stability (RS), and sustained high rate (SHR). False positive rates (tachycardia response inappropriately triggered by ST) were as follows: HR (93%); HR + SO (3%); HR + RS (63%); HR + (RS or SHR) (87%); HR + HS + SO (8%). Pair-wise significance testing between HR only and HR + SO (p < 0.001), HR + RS (p = 0.01) and HR + SO + RS (p < 0.001), demonstrated a significant reduction in the rate of false positives through the use of the sudden onset and rate stability criteria in concert with the standard high rate criterion.     

Effect of thyrocytes from transgenic mice expressing thyroid specific MHC class Ⅱ on autologous T lymphocyte in vitro

Thyrocytes expressing MHC class Ⅱ molecules were separated from transgenic mice and were co-cultured with autologous spleen T lymphocytes. T cells did not proliferate and were not activated, but CD4+ T cells were promoted into apoptosis.     

继发性肝癌的外科治疗

目的探讨继发性肝癌的手术适应证和方法。方法对52例继发性肝癌的临床病例资料进行回顾性分析。结果分别采用了左半肝切除、右半肝切除、左外叶切除、右前叶切除、右后叶切除和肝楔形切除术。术后1、3、5年的生存率分别为28.3%、19.4%和11.9%。结论对适合手术的继发性肝癌,行肝切除术可以获得满意的效果。     

他汀类药物对心血管的保护作用

他汀类药物(statins)被研制出来的最初目的是降低血脂,但是现在发现它不仅具有降低血脂的作用,还具有很多其他的作用包括改善内皮细胞功能的紊乱,提高内皮源性一氧化氮合成酶的生物活性,抑制血管平滑肌细胞的增殖,抗氧化作用,抗炎作用,降低血压,逆转心血管系统的重构。充分理解statins的多效性作用及机制有利于它更好的在临床中被应用于心血管系统的预防和治疗。     

Preventive dental prosthesis for the patient with bulimia

Bulimia is a distinct diagnostic eating disorder with its most noted manifestation being the rapid ingestion of large quantities of food followed by its elimination through the mouth. Because of the dental implications of highly acidic stomach contents chronically being regurgitated, the dentist is in a unique position to help identify the patient with bulimia. Dental erosion is not only the most easily noted but also the most destructive of the many oral problems caused by bulimia. This report of case describes a preventive dental prosthesis that can be used by the patient with bulimia to protect those teeth that are most affected by dental erosion. The construction of the prosthesis is easily completed with materials in the dental office and provides a great service to the patient with bulimia.     

慢性丙型肝炎患者α干扰素和α干扰素受体1的检测

目的建立检测外周血单个核细胞α干扰素受体1(IFNAR1)及检测诱导表达α干扰素(IFN-α)的方法,评价慢性丙型肝炎患者外周血单个核细胞(PBMC)细胞免疫功能与α干扰素治疗的关系。方法Poly IC体外刺激正常对照组和慢性丙型肝炎病毒(HCV)感染组患者PBMC,利用病毒保护试验研究干扰素治疗前后患者PBMC表达的干扰素抗病毒生物学活性差异;IFN-α治疗前后,RT-PCR检测慢性丙型肝炎患者不同干扰素应答组患者PBMC IFNAR1表达的变化。结果对照组PBMC分泌的干扰素活性显著高于慢性丙型肝炎患者应答组患者(P<0.001);干扰素应答组患者PBMC分泌的干扰素活性随治疗时间延长而增加,治疗1个月后显著高于无应答组患者PBMC分泌的干扰素活性(P<0.01),后者始终处于低下水平;IFN-α治疗期间干扰素应答组患者PBMC IFNAR1水平从治疗前的高表达而逐渐减少,正常对照和干扰素无应答组患者PBMC IFNAR1的表达始终较低。结论慢性HCV感染患者的细胞免疫功能受损,不能正常表达IFN-α,但应答组患者经干扰素治疗后IFN-α表达能力逐渐恢复;干扰素无应答组患者PBMC IFNAR1表达受到严重抑制;慢性丙型肝炎患者PBMCIFN-α活性检测及IFNAR1检测结果也许可以作为干扰素治疗预后的判断指标。     

胃癌腹腔冲洗液多巴脱羧酶mRNA的检测

目的：通过检测胃癌腹腔冲洗液中DDCmRNA的表达，探讨多巴胶羟酶（DDC）与胃癌腹膜转移的关系，并为胃癌腹膜转移预测和亚临床转移的筛检提供新的方法．方法：用RNA提取和RT-PCR方法检测92例胃癌腹腔冲洗液中DDCmRNA的表达，同时做腹腔冲洗细胞学（PLC）检查；10例良性疾病的腹腔冲洗液作为阴性对照，结果：92例胃癌腹腔冲洗液中有57例检测到DDCmRNA的表达（62．0％），其表达阳性率与胃癌腹膜转移的PS因素密切相关（P〈0．05）；且胃癌腹腔冲洗液中DDCmRNA的表达水平还与胃癌浸润深度、浆膜类型、PLC检查结果以及是否存在肉眼腹膜转移有关，浸润深度深、浆膜受侵程度重、PLC检查结果阳性及存在肉眼腹膜转移病灶者的DDCmRNA表达相对值明显升高（P〈0．05）；而10例良性疾病腹腔冲洗液均未检测到DDCmRNA的表达．结论：胃癌腹腔液中DDCmRNA的表达与胃癌腹膜转移密切相关，通过RT—PCR来检测DDCmRNA适用于胃癌腹膜转移的预测和亚临床转移的筛检。     

芪月降脂片制剂处方的优化

[目的 ]优化芪月降脂片的制剂处方 .[方法 ]采用正交设计和多指标综合评分法对已筛选出的药剂辅料进行处方优化 .[结果 ]最佳制剂处方为糖粉 50 g ,辅料X 50g ,微晶纤维素 75g .[结论 ]该处方合理 ,成型性好